Cleaved HIV-1 Env Glycoprotein Trimer Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The development of vaccines that induce broadly neutralizing antibodies (bNAbs) against HIV-1 infection is hindered by the instability and non-native configuration of soluble HIV Env glycoproteins, particularly the BG505 SOSIP.664 gp140 trimers, which are crucial for preventing virus entry into target cells.
Innovation Solution
An expression vector system that integrates into mammalian cells, co-expressing HIV Env glycoproteins and furin protease, with optimized promoters for controlled expression, ensures the production of stable, cleaved, and native-like Env glycoproteins, facilitating the generation of mammalian cell lines that produce high-quality, cleaved Env glycoproteins for pre-clinical and clinical applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If soluble gp140 proteins are produced without sequence modifications, then production is simpler, but the proteins are highly unstable and disintegrate or adopt non-native configurations
Solution Approach 1:
The patent applies parameter changes by modifying specific amino acid sequences in the gp140 protein (SOSIP modifications including disulfide bond formation and point substitutions) to alter its stability parameters. These sequence modifications change the physical-chemical properties of the protein, enabling it to maintain native-like configurations and resist disintegration while remaining soluble.
Solution Approach 2:
The patent creates a composite structure by introducing a disulfide bond (SOS) that links gp120 and gp41ECTO components, effectively combining them into a stable complex. This composite approach uses the disulfide bridge as a molecular connector to maintain the integrity of the trimeric structure without requiring full integration into the viral particle.
2Productivity
If furin protease is co-expressed to facilitate cleavage, then cleavage efficiency improves, but expression balance becomes difficult to control
Solution Approach 1:
The patent uses an intermediary approach by introducing a furin protease recognition site (cleavage site) into the gp160 sequence. This cleavage site acts as a mediator that allows specific proteolytic cleavage between gp120 and gp41 by furin protease, enabling controlled separation of the subunits while maintaining overall expression balance through the regulated presence of the recognition sequence.
3Quantity of substance
If high levels of Env glycoprotein are produced for vaccine development, then sufficient quantity for clinical use is achieved, but protein aggregation and instability increase
Solution Approach 1:
The patent applies parameter changes through SOSIP modifications that alter the stability parameters of gp140, allowing it to remain stable at high concentrations. The disulfide bond formation and point substitutions change the energy landscape of the protein, preventing aggregation even when produced at high levels suitable for vaccine development.
Solution Approach 2:
The patent creates a soluble copy (gp140) that mimics the native viral Env spike structure. By producing this soluble copy with modified stability properties, the system achieves high-level expression without the aggregation problems that would occur with native viral proteins, enabling sufficient quantity for clinical applications while maintaining structural integrity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of high-quality, cleaved HIV Env glycoproteins with enhanced stability and native-like configuration, supporting the generation of bNAbs and improving the efficacy of HIV vaccine development by providing sufficient quantity and quality for research and clinical use.
Implementation Method 1
Proteolytic cleavage between the gp120 and gp41 subunits is also critical for making native-like trimers
Implementation Method 2
a disulfide bond (designated SOS) to link the gp120 and gp41 ectodomain (gp41ECTO) components
Data Source
AI summary
Expression vectors and mammalian cell lines containing them are described that enable the recombinant production of HIV-1 envelope proteins, including SOSIP modified gp140 trimers capable of inducing broadly neutralizing antibodies.